Clinical Trial: Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Liposarcoma, Dedifferentiated
Study Type: INTERVENTIONAL
Official Title: Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Ded
Brief Summary:
This study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS).They can join the study if their tumours are positive for MDM2.The purpose of this study is to find out whether a medicine called brigimadlin (BI 907828) is tolerated by and helps people with DDLPS.Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer.Participants take brigimadlin as a tablet once every 3 weeks.Participants may continue to take brigimadlin as long as they benefit from…
Read more